Biomolecules and Biomedicine

29/12/2025

Induced Sputum KL-6 and HRCT Scoring in Idiopathic Pulmonary Fibrosis

This prospective study suggests induced sputum KL-6 can distinguish IPF from healthy controls and reflects disease burden through strong links with DLCO impairment and HRCT fibrosis scoring. Combining KL-6 with a structured HRCT score achieved very high diagnostic performance (AUC 0.936; specificity 97.5%), indicating a practical biomarker plus imaging approach worth validating in larger, real-world IPF cohorts.

Read more below:
Author summary: https://blog.bjbms.org/induced-sputum-kl-6-and-hrct-scoring-in-idiopathic-pulmonary-fibrosis/
Research article: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12667/4004

Induced Sputum KL-6 and HRCT Scoring in Idiopathic Pulmonary Fibrosis: elevated KL-6 correlates with DLCO and fibrosis score, improving diagnosis.

26/12/2025

Prof. Luca Testarelli: Bridging Restorative Dentistry, Endodontics, and Digital Innovation (Interview)

We are pleased to announce that Prof. Luca Testarelli has been recently appointed Associate Editor of Biomolecules and Biomedicine - supporting rigorous peer review, interdisciplinary dialogue, and the journal’s international visibility.

How do we truly connect clinical reality with scientific rigor in modern dentistry?

In our latest interview, Prof. Testarelli, Full Professor at Sapienza University of Rome, shares a perspective shaped by decades of parallel commitment to clinical practice and academic research, with a clear message: integration is no longer optional; it is essential.

With 330+ publications and 11,000+ citations, his work spans:
• restorative dentistry and endodontics
• dental biomaterials and implantology
• oral surgery
• digital and 3D technologies transforming clinical workflows

Read the full interview here: https://blog.bjbms.org/prof-luca-testarelli-bridging-restorative-dentistry-endodontics-and-digital-innovation/

Prof. Luca Testarelli: Bridging Restorative Dentistry, Endodontics and Digital Innovation—Sapienza professor, new BB Associate Editor.

26/12/2025

SHR and SIRI Improve CHD Detection in Type 2 Diabetes

Can two routinely available indices, one reflecting acute-on-chronic glycemic stress and the other systemic inflammation, meaningfully sharpen CHD risk stratification in T2DM? New angiography-based evidence suggests that combining SHR and SIRI significantly improves discrimination beyond either marker alone, with clear implications for earlier identification of high-risk patients.

Read more below:
Author summary: https://blog.bjbms.org/shr-and-siri-improve-chd-detection-in-type-2-diabetes/
Research article: https://www.bjbms.org/ojs/index.php/bjbms/article/view/13032

SHR and SIRI Improve CHD Detection in Type 2 Diabetes: angiography study shows combined indices boost risk stratification vs either alone.

24/12/2025

IRF5 Variants Linked to Rheumatoid Arthritis Risk in Mexican Women

A Central Mexico case–control study reports significant RA associations for IRF5 variants rs2004640, rs2070197, and rs10954213—pointing to interferon/cytokine signaling as a population-relevant risk pathway in women.
With suggestive functional hints (splice effects, eQTL signals, 3′UTR polyadenylation) but non-additive haplotype risk, the findings highlight why replication and mechanistic follow-up could reshape how we interpret IRF5’s role in RA susceptibility.

Read more below:
Author summary: https://blog.bjbms.org/irf5-variants-linked-to-rheumatoid-arthritis-risk-in-mexican-women/
Full research article: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12919

IRF5 Variants Linked to Rheumatoid Arthritis Risk in Mexican Women—case–control study in Central Mexico ties rs2004640, rs2070197, rs10954213 to RA.

22/12/2025

Small cell lung cancer (SCLC): At the door of targeted therapies

After decades of limited progress and near-universal relapse, DLL3- and B7-H3–directed strategies are showing clinically meaningful activity in extensive-stage SCLC—highlighting tarlatamab’s survival advantage and strong late-line responses with I-DXd. The next research question is no longer whether targets exist, but how to sequence and combine these agents, manage BiTE-specific toxicities (CRS/ICANS), and develop biomarkers that can reliably guide patient selection across SCLC subtypes.

Read more below:
Author Summary: https://blog.bjbms.org/small-cell-lung-cancer-sclc-at-the-door-of-targeted-therapies/
Full Editorial: https://www.bjbms.org/ojs/index.php/bjbms/article/view/13195

Small cell lung cancer (SCLC): At the door of targeted therapies—overview of relapse, DLL3/B7-H3 targets, and new agents tarlatamab and I-DXd.

19/12/2025

Topical Nitroglycerin Improves Skin Flap Survival by Boosting Blood Vessel Growth

In a standardized rat dorsal skin flap model, continuous topical nitroglycerin was associated with a marked increase in pedicle-independent viable area after day-5 pedicle division (≈84% vs ≈30% in controls; P

Topical Nitroglycerin Improves Skin Flap Survival by Boosting Blood Vessel Growth; continuous dosing raised pedicle-independent viability in rats.

17/12/2025

TUBB, CLTA, and FBXL5 as Blood Markers for Postmenopausal Osteoporosis

By moving the focus from bone tissue to peripheral blood, this research offers a different perspective on osteoporosis biology. The findings raise important questions about immune regulation, RNA modification, and their relevance to disease heterogeneity.

Read more below:
Author summary: https://blog.bjbms.org/tubb-clta-and-fbxl5-as-blood-markers-for-postmenopausal-osteoporosis/
Research article: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12019

Identifies TUBB CLTA and FBXL5 as Blood Markers for Postmenopausal Osteoporosis, using peripheral blood gene expression analysis.

15/12/2025

Extraovarian fibrothecoma: a benign tumor that can mimic ovarian cancer

Elevated CA-125, ascites, and postmenopausal pelvic masses usually trigger an oncologic alarm—but what if the diagnosis is benign? This rare extraovarian entity highlights critical diagnostic pitfalls and underscores the importance of careful morphologic and immunohistochemical evaluation to avoid overtreatment.

Read more below:
Author summary: https://blog.bjbms.org/extraovarian-fibrothecoma-a-benign-tumor-that-can-mimic-ovarian-cancer/
Full case report with review: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12816

Extraovarian fibrothecoma: a benign tumor that can mimic ovarian cancer, often presenting with ascites and elevated CA-125.

12/12/2025

How Tumors Rewire Glucose Metabolism to Escape Copper-Induced Cell Death

A recent review outlines how aerobic glycolysis, PPP-driven NADPH/GSH, and PDK-mediated PDH inhibition can jointly suppress cuproptosis by limiting lipoylated mitochondrial targets and buffering copper stress. If your work touches tumor metabolism or metal biology, the proposed combination strategies—reactivating TCA flux while constraining NADPH/GSH and pairing with copper ionophores—are worth a closer look.

Read more below.
Author summary: https://blog.bjbms.org/how-tumors-rewire-glucose-metabolism-to-escape-copper-induced-cell-death/
Full review: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12751

How Tumors Rewire Glucose Metabolism to Escape Copper-Induced Cell Death: review links glycolysis/PPP, NADPH-GSH and PDKs to cuproptosis resistance.

10/12/2025

Presepsin shows strong potential for improving sepsis diagnosis

A review of 47 studies brings new clarity to presepsin’s role in detecting sepsis earlier and more reliably. Researchers may find the age-specific performance and methodological comparisons particularly impactful for future diagnostic strategies.

Read more below:
Author summary: https://blog.bjbms.org/presepsin-shows-strong-potential-for-improving-sepsis-diagnosis/
Full meta-analysis: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12909

Presepsin Shows Strong Potential for Improving Sepsis Diagnosis by supporting faster, reliable detection and helping identify sepsis earlier.

10/12/2025

The Reviewer of the Month for December 2025: Marko Bojović, MD

Peer review is fundamental to ensuring the rigor and reliability of scientific publishing. This month, Biomolecules and Biomedicine proudly highlights Dr. Marko Bojović as our Reviewer of the Month for December 2025.

Dr. Bojović is a Radiation Oncologist at the Oncology Institute of Vojvodina and an Assistant at the University of Novi Sad. His research covers a wide range of oncology topics—including optimized radiotherapy schedules, diagnostic approaches in lung cancer, and long-term studies of ultrahypofractionated radiotherapy.

His reviews are consistently comprehensive, constructive, and grounded in deep clinical expertise. We are grateful for his commitment to maintaining high standards in peer review and supporting ongoing scientific progress.

Read our full interview with Dr. Marko here: https://blog.bjbms.org/the-reviewer-of-the-month-for-december-2025-marko-bojovic-md/

The Reviewer of the Month for December 2025: Marko Bojović, MD, recognized for excellence in peer review and advancing scientific publishing quality.

08/12/2025

Sugammadex vs. Neostigmine: New Evidence on Post-Anesthesia Recovery

What if the drugs used at the end of surgery could change a patient’s immediate safety and comfort just as much as the anesthesia itself? A new analysis shows surprising differences in how two commonly used reversal agents shape recovery, and why those differences matter more than most people realise.

Read more below:

Author summary: (FIND LINK IN BIO).